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Abstract: Apium graveolens (celery) is an edible and traditionally medicinal plant that is used
worldwide, among others for the treatment of hypertension. Combining celery with antihypertensive
drugs can affect the pharmacodynamics and pharmacokinetics of the latter drugs. The aim of the
study is to assess the effects of administrating the celery extract on captopril pharmacokinetics.
Sprague-Dawley strain rats were divided into two groups (n = 6). Group I was given captopril
(10 mg/kg Body Weight (BW)) orally, while Group II was pretreated with celery extract orally
(40 mg/kg BW) an hour before administration of captopril. The blood samples were withdrawn
at various intervals after drug administration. The captopril concentration was determined using
liquid chromatography–mass spectrometry (LC-MS/MS) and from the blood data, the values of Ke,
Cmax, Tmax, T1/2, and area under the curve (AUC) were calculated. The results showed that oral
administration of the celery extract increased Cmax (38.67%), T1/2 (37.84%), and AUC (58.10%) and
decreased Ke (27.45%) of captopril in Group II (celery + captopril) compared with Group I (captopril).
In conclusion, celery extract can alter the pharmacokinetic of captopril when given in combination.
The combination might be beneficial for the treatment of hypertension, as celery causes an increase in
the plasma level of captopril, which can enhance its efficacy.
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1. Introduction
Celery (Apium graveolens) is usually used in traditional medicine as a diuretic or anti-hypertensive
agent. It contains chemical compounds such as apiin, apigenin, isoquercitrin, and sesquiterpene [1,2].
Celery has been sold as food supplement, so the pharmaceutical industries do not need to prove
the efficacy of the herbs or determine the side effects or interactions between the products [3].
Most people believe that herbs are harmless plants but can affect body functions. In fact, in Indonesia,
herbs are frequently used as traditional medicines for various diseases. Since herbs are widely
available, people can easily use them alone or in combination with synthetic drugs. There is limited
knowledge about herbs, and interactions may occur when herbs are taken together with synthetic
drugs [3]. The mechanisms of drug interactions can be divided into several general categories,
including pharmacokinetics (absorption, distribution, metabolism, and excretion of a drug) and
pharmacodynamics (the combined pharmacological effects of a drug) [3]. Combining synthetic drugs
with herb preparations may have a synergistic effect or can increase the rate of side effects [4].
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Captopril is widely used as an antihypertensive agent and for heart failure. It is the first drug
from the class of angiotensin converting enzyme inhibitors (ACEis), which works by preventing
the conversion of angiotensin I into angiotensin II (potential vasoconstrictor and aldosterone
secretion stimulant agent). ACE inhibitors prevent the degradation of bradykinin and stimulate
the synthesis of compounds, including other vasodilators, such as prostaglandin E2 and prostacyclin.
Decreased secretion of aldosterone causes sodium and water excretion as well as potassium retention.
Subsequently, this causes a decline in blood pressure in patients with hypertension [5].
Captopril and celery have been used in Indonesia to treat hypertension [6]. Previous research has
provided evidence that 73% of patients in public hospitals have used captopril as an antihypertensive
drug [7]. Other research has shown that there was evidence that 71.4% of patients in the public
community health center have combined celery herbs with captopril, finding that this combination is
able to reduce blood pressure better than captopril alone [8]. Another study reported that celery juice
has the potential to modulate cytochrome P450 activity and thus can interact with synthetic drugs [9].
Therefore, the exact mechanisms of the captopril–celery interaction are unknown. We aimed to study
the interaction of celery with captopril to evaluate the pharmacokinetic interaction of captopril with
celery using rat as the experimental animal model.
2. Materials and Methods
2.1. Experimental Animals
White male Sprague-Dawley rats used in this experiment were obtained from the Bogor
Agricultural University (IPB), Bogor, West Java, Indonesia; weighing 200–250 g. The rats were housed
at 25± 5 ◦C in a well-ventilated animal house under a 12:12 h light/dark cycle. The rats had free access
to food and water. The study protocol has been approved by the Health Research Ethics Committee of
the Faculty of Medicine, Universitas Indonesia, Central Jakarta, Indonesia. The reference number for
approval was 666/UN2.F1/ETHICS/2016.
2.2. Preparation of Celery Extract and Physicochemical Evaluation
Fresh celery (Apium graveolens) was purchased from the local market. The plant was identified at
The Research Center for Biology, Indonesian Institute of Sciences (LIPI), Cibinong, West Java, Indonesia;
with the determination specimen number of 1777/IPH.1.01/if.07/VIII/2016. The identification of
the plant was conducted to determine the classification of the plants [10]. Celery herbs were rinsed
with running water. The small cut pieces of the sample were dried at room temperature or in the
oven to prevent microbial fermentation and the degradation of metabolites as well as to minimize
chemical reactions that were induced by ultraviolet rays from direct sunlight. After this, the dried
celery powders were macerated using 50% ethanol for three days. The extract was separated by
filtration using filter paper and was concentrated using rotary vacuum evaporator (Buchi, Darmstadt,
Germany). The viscous extract was collected and stored at 4 ◦C before used [11].
The physico-chemical characteristics of the extract were determined according to methods
described by WHO guidelines on the quality control methods for medicinal plant materials [12]
and the standard for medicinal plant extract through the following quality parameters: water content,
total ash content, loss on drying, and essential oil content [13].
2.3. Chromatography
The chromatography was performed on C18 column Acquity (Waters, Milford, CT, USA)
(100 mm × 2.1 mm), with a particle size of 1.7 µm at a temperature of 40 ◦C. The gradient system of
the mobile phase composition was a mixture of 0.1% formic acid and acetonitrile (60:40 v/v), with
a flow rate of 0.3 mL/second. For mass detection, we used a Waters Xevo Triple Quadrupole (Waters)
equipped with an electrospray ionization (ESI) source in positive ions in multiple reaction monitoring
(MRM) mode.
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2.4. Preparation of the Standard Solution: Calibration Standards and Quality Control Sample Preparation
A stock solution of captopril with a concentration of 100 µg/mL was prepared by dissolving
40 mg in 100 mL of water. A stock solution of propranolol (1 mg/mL) and apigenin (1 mg/mL) was
prepared by dissolving 40 mg in 100 mL of methanol. Calibration standards and the Quality Control
(QC) sample were prepared by diluting the stock solution with Sprague-Dawley rat plasma to form
the calibration standards of captopril in the presence of apigenin (3, 6, 12, 25, 50, and 100 ng/mL) and
QC sample (9, 40, and 80 ng/mL). A stock solution of 2,4-dibromo acetophenone with a concentration
of 520 µg/mL was prepared by dissolving 52 mL in 100 mL of methanol.
2.5. Preparation of Plasma Sample
A simple protein precipitation procedure was applied to clean up the plasma sample before
use [14]. A total of 180 µL of plasma containing the specific concentration of captopril and apigenin was
added to 20 µL of 2,4-dibromo acetophenone working solution and 5% ammonia solution. After this,
the solution was vortexed for 30 s and stored at 25 ◦C for 30 min, before adding 20 µL of 15% formic acid,
propranolol (1 µL/mL), and 600 µL of acetonitrile. The solution was vortexed for 30 s and centrifuged
at 12,000 rpm for 5 min. The supernatant was transferred to an autosampler vial, before 5 µL was
injected into the liquid chromatography–mass spectrometry (LC-MS/MS) system.
2.6. Pharmacokinetic Study
Twelve rats were divided into two groups: Group I received a single captopril at a dose of
10 mg/kg orally, while Group II was pretreated with the celery extracts orally (40 mg/kg) an hour
before the administration of captopril. Serial blood samples (0.5 mL per sample) were collected before
dosing and after 10, 20, 30, 45, 60, 120, 180, 300, and 420 min. The harvested plasma samples were
treated in the pre-used plasma preparations mentioned before. The captopril concentration was
determined using LC-MS/MS, and the values of elimination constant (Ke), maximum concentration
(Cmax), maximum time (Tmax), half-time (T1/2), and area under the curve (AUC) were calculated based
on this blood data.
The data were represented in a plasma level–time curve, which was used to calculate the AUC0-7h
using the trapezoid rule. The Cmax and Tmax were obtained directly from the generated data. The Ke
and T1/2 were determined from the semi-log plot of the data. The mean plasma concentration–time
curve for captopril (10 mg/kg) alone and captopril + celery extract (40 mg/kg) was determined.
The study was conducted for 7 h since the half-life of captopril is 1–2 h [15]. The results were analyzed
statistically using the Student’s T-test.
3. Results
3.1. Physico-Chemical Characteristics
The physicochemical characteristics, such as weight loss after drying, ash values, water content,
and essential oil content, are given in Table 1.
Table 1. Physicochemical characteristics of celery extract.
Parameter Celery Extract
Ash values (%) w/w 6.70%
Water content (%) v/w 8.89%
Essential oil (%) v/w 3.34%
Loss on drying (%) w/w 4.87%
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3.2. Optimization of LC-MS/MS Parameters
For mass detection, we used Water Xevo TQD (Waters) equipped with electrospray ionization
(ESI) source in positive ions in multiple reaction monitoring (MRM) mode. The following operational
parameters of the ion cone and collision energies are presented in Table 2. Captopril was detected at
an m/z of 271.13 > 153.07, while propranolol was detected at an m/z of 260 > 183.17, which was used as
an internal standard.
Table 2. The result of optimization detection of liquid chromatography–mass spectrometry
(LC-MS/MS).
Compound Parent (m/z) Daughter (m/z) Cone (V) Collison (V) Area
Captopril 415 216.16 35 17 3.05 x 105
Propranolol 260 183.17 42 17 5.59 x 106
Apigenin 271.13 153.07 61 31 7.03 x 106
3.3. Calibration Curve and Lower Limit of Quantification (LLOQ)
The curves of calibration were found to be linear, over the concentration range of 3–100 ng/mL
and with a linearity of 0.9961, and the lower limit of quantification (LLOQ) was 3 ng/mL. The precision
value (%CV) of within-run analysis was 6.91–8.37%, which is less than 20% (Table 3).






3 3.13 ± 0.25 7.91 4.46
9 8.46 ± 0.71 8.37 −5.82
40 39.36 ± 2.93 7.46 −1.41
80 77.37 ± 5.34 6.91 −3.10
3.4. Pharmacokinetics
The pharmacokinetics of the combined captopril and celery extract were subsequently examined
in Sprague-Dawley rats after oral administration. The pharmacokinetic parameters are listed in Table 4
and Figure 1. The Cmax and AUCtotal was reached in Group II compared with Group I, although there
were no significant differences (p > 0.05).
Table 4. Pharmacokinetic parameters of captopril.
Pharmacokinetic
Parameters
Group I (n = 6)
(single captopril)
Group II (n = 6)
(captopril + celery extract)
Cmax (ng/mL) 100.63 ± 28.62 127.86 ± 29.30
Tmax (hour) 0.16 0.16
Ke (hour−1) 0.2391 ± 0.08 0.2162 ± 0.07
T1/2 (hour) 1.8578 ± 3.67 4.7029 ± 1.05
AUCtotal 99.11 ± 13.05 158.28 ± 25.64
Values are mean ± SEM, p > 0.05 when compared to captopril alone. AUC: area under the curve; Cmax: maximum
concentration; Tmax: maximum time; Ke: elimination constant; T1/2: half-time.
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Figure 1. Pharmacokinetics of captopril. Plasma captopril levels were measured with LC-MS/MS. 
Symbols represent the mean concentration ± standard error of the mean (SEM). Group I (n = 6) was 
given a single dose of captopril (10 mg/kg, orally), while Group II (n = 6) was given captopril (10 
mg/kg) with celery extract (40 mg/kg, orally).  
4. Discussion 
The physico-chemical characteristics of celery extract determine their quality. Water content or 
moisture is sufficient to facilitate the activation of enzymes and the proliferation of microorganisms. 
These are inevitable components of crude medicines and must be eliminated as much as possible. 
Ash values are useful in determining the authenticity and purity of a drug as well as its critical 
quantitative standards. The total ash value of the extract provides an indication of earthy matter or 
mineral composition as well as the impurities present. The quality of herbal medicines can be affected 
by many factors, such as light exposure, temperature, water availability, the amount of nutrients, the 
period and time of collection, the methods by which the medicine is collected, dried, packed, stored, 
and transported, age, and which part of the plant is collected [12,13].  
Captopril is an unstable compound that undergoes oxidation. The degradation product is a 
dimer that also binds to endogenous compounds (cysteine and glutathione) [15]. A derivatizing 
agent, 2,4-dibromo acetophenone, was added to improve the stability of the compound, which 
prevents captopril from binding to plasma constituents and is also a chemical stabilizer [15]. 
The precision and accuracy of captopril in the presence of apigenin (a marker from celery extract) 
were calculated by our within-run variation of QC samples at four different concentrations with five 
replicates. The precision (%CV) value from the within-run analysis is 6.91–8.37%, while the accuracy 
(%diff) of captopril is less than 20%. The accuracy and precision values indicate the adequate 
reliability and reproducibility of the method within an analytical range [16].  
The pharmacokinetic parameter values of captopril were calculated (Table 4). The celery extract 
was administered one hour before captopril in order to ensure that there was no interaction with the 
absorption of captopril. The pharmacokinetic interaction appears to occur at the cytochrome P450 
level [17,18].  
The calculation of pharmacokinetic parameters showed that the concomitant use of captopril 
and celery extract increased the plasma levels (Cmax) by 38.67% and AUCtotal, of captopril, although 
there were no significant differences (p > 0.05). The time needed to reach the peak (Tmax) plasma 
concentration of captopril occurred at the same time in both groups. There was prolonged elimination 
half-life (T1/2) of captopril in the presence of celery from 2.93 to 4.03. Although there were no 



























Figure 1. Pharmacokinetics of captopril. Plasma captopril levels were measured with LC-MS/MS.
Symbols represent the mean concentration ± standard error of the mean (SEM). Group I (n = 6)
was given a single dose of captopril (10 mg/kg, orally), while Group II (n = 6) was given captopril
(10 mg/kg) with celery extract (40 mg/kg, orally).
4. Discussion
The physico-chemical characteristics of celery extract determine their quality. Water content or
moisture is sufficient to facilitate the activation of enzymes and the proliferation of microorganisms.
These are inevitable components of crude medicines and must be eliminated as much as possible.
Ash values are useful in d termining the authenticity and purity of a drug as well as its c itical
quantitative standards. Th total ash value of the extract provides an indication of e rthy mat r or
mineral composition as well as the impurities p esent. The quality of herbal medicines can be affected
by many factors, such as light exposure, temperature, water availability, the amount of nut ients,
the period and time of collection, the methods by which the medicine is collected, dried, packed,
stored, and transported, age, and which part of the plant is collected [12,13].
Captopril is an unstable compound that undergoes oxidation. The degradation product is a dimer
that also binds to endogenous compounds (cysteine and glutathione) [15]. A derivatizing agent,
2,4-dibromo acetophenone, was added to improve the stability of the compound, which prevents
captopril from binding to plasma constituents and is also a chemical stabilizer [15].
The precision and accuracy of captopril in the presence of apigenin (a marker from celery extract)
were calculated by our within-run variation of QC samples at four different concentrations with five
replicates. The precision (%CV) value from the within-run analysis is 6.91–8.37%, while the accuracy
(%diff) of captopril is less than 20%. The accuracy and precision values indicate the adequate reliability
and reproducibility of the method within an analytical range [16].
The pharmacokinetic parameter values of captopril were calculated (Table 4). The celery extract
was administered one hour before captopril in order to ensure that there was no interaction with the
absorption of captopril. The pharmacokinetic interaction appears to occur at the cytochrome P450
level [17,18].
The calculation of pharmacokinetic parameters showed that he concomitant use of captopril
and cel ry extract increased the plasma levels (C ax) by 38.67% and AUCtotal, f captopr l, alth ugh
there were no significant differences (p > 0.05). The time needed to reach t e peak (Tmax) plasma
conce tration of captopril occurred at the same time in both groups. There was prolo ged elimination
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half-life (T1/2) of captopril in the presence of celery from 2.93 to 4.03. Although there were no significant
differences (p > 0.05), the upward trend of Cmax and AUC of captopril combined with celery extract in
our study suggests that celery extract was a potent inhibitor of cytochrome P450, which is responsible
for captopril metabolization [9].
Therefore, if captopril is taken along with celery, this will inhibit the metabolism of captopril.
A previous study showed that captopril has pharmacodynamical interactions when combined with
garlic, which has the synergetic effect of preventing the damage caused by isoproterenol in rats [19].
The mechanism of action for many herbs has not been determined and the exact mechanisms of
drug–herb interaction are also unknown [20]. To our knowledge, this is the first report showing the
possible pharmacokinetics interaction of celery extract when combined with captopril.
5. Conclusions
The administration of celery extracts, when given in combination with captopril, can increase the
bioavailability of captopril which is probably caused by inhibition of the cytochrome P450 responsible
for captopril catabolism
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